SCHEMBL26104036

SCHEMBL26104036

C=Cc1cnc2[nH]ccc2c1C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 7/20 0.42
▸ RET P07949 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ LTK P29376 1/20 0.42
▸ GRK5 P34947 1/20 0.42
▸ BTK Q06187 1/20 0.42
▸ MAP4K2 Q12851 1/20 0.42
▸ STK33 Q9BYT3 1/20 0.42
▸ NUDT1 P36639 1/20 0.41
▸ CDK8 P49336 1/20 0.40
▸ AXL P30530 5/20 0.39
▸ PRKCI P41743 1/20 0.39
▸ TTBK1 Q5TCY1 1/20 0.39
▸ TTBK2 Q6IQ55 1/20 0.39
▸ MAP2K1 Q02750 1/20 0.38
▸ JAK1 P23458 6/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31347193 1.00 JAK3 (0.42) JAK3RETFGFR1LTKGRK5
SCHEMBL26107823 0.81 TTBK1 (0.49) JAK3NUDT1CDK8AXLPRKCI
SCHEMBL1953766 0.79 TTBK1 (0.43) JAK3NUDT1CDK8AXLPRKCI
SCHEMBL31347303 0.79 AXL (0.47) JAK3NUDT1CDK8AXLPRKCI
SCHEMBL9938223 0.79 AXL (0.47) JAK3NUDT1CDK8AXLPRKCI
SCHEMBL15372867 0.79 TTBK1 (0.43) JAK3RETFGFR1LTKGRK5
SCHEMBL31347207 0.78 NUDT1 (0.48) JAK3NUDT1CDK8AXLPRKCI
SCHEMBL26107917 0.78 NUDT1 (0.48) JAK3NUDT1CDK8AXLPRKCI
SCHEMBL31403755 0.72 NUDT1 (0.50) JAK3NUDT1CDK8AXLPRKCI
SCHEMBL2632955 0.72 NUDT1 (0.50) JAK3NUDT1CDK8AXLPRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 — — US disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 — — CN disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 — — EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 JAK3 3015/4885RET 3972/4885FGFR1 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback